Pacira Cost Of Revenue vs Net Income Analysis
PCRX Stock | USD 30.32 0.63 2.12% |
Pacira Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pacira Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacira Pharmaceuticals is a good investment. Please check the relationship between Pacira Pharmaceuticals Cost Of Revenue and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.
Cost Of Revenue vs Net Income
Cost Of Revenue vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacira Pharmaceuticals Cost Of Revenue account and Net Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Pacira Pharmaceuticals' Cost Of Revenue and Net Income is 0.58. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income in the same time period over historical financial statements of Pacira Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pacira Pharmaceuticals' Cost Of Revenue and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Pacira Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Cost Of Revenue i.e., Pacira Pharmaceuticals' Cost Of Revenue and Net Income go up and down completely randomly.
Correlation Coefficient | 0.58 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Cost Of Revenue
Cost of Revenue is found on Pacira Pharmaceuticals income statement and represents the costs associated with goods and services Pacira Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Pacira Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Pacira Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Pacira Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacira Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.At this time, Pacira Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.33 in 2024, whereas Selling General Administrative is likely to drop slightly above 63.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 31.8M | 40.0M | 23.8M | 16.1M | Depreciation And Amortization | 13.6M | 61.4M | 75.6M | 79.4M |
Pacira Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Pacira Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pacira Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 831.1M | 1.3B | 2.1B | 1.7B | 1.6B | 1.7B | |
Other Current Liab | 18.2M | 14.7M | 117.9M | 89.8M | 64.2M | 36.3M | |
Total Current Liabilities | 107.7M | 253.3M | 521.1M | 147.8M | 97.4M | 123.5M | |
Total Stockholder Equity | 354.9M | 619.7M | 730.4M | 775.0M | 870.1M | 913.6M | |
Other Liab | 21.5M | 17.4M | 77.6M | 37.8M | 43.5M | 24.9M | |
Property Plant And Equipment Net | 142.8M | 211.2M | 264.8M | 254.4M | 234.9M | 120.3M | |
Net Debt | 273.7M | 441.2M | 543.3M | 659.3M | 432.7M | 454.4M | |
Retained Earnings | (399.4M) | (253.9M) | (211.9M) | (148.8M) | (106.8M) | (112.1M) | |
Accounts Payable | 12.8M | 10.4M | 10.5M | 15.2M | 15.7M | 10.4M | |
Cash | 78.2M | 100.0M | 585.6M | 104.1M | 153.3M | 117.4M | |
Non Current Assets Total | 422.5M | 622.9M | 1.2B | 1.2B | 1.1B | 1.1B | |
Non Currrent Assets Other | 11.0M | 74.5M | 76.4M | 27.2M | 36.0M | 37.9M | |
Other Assets | 971K | 290.1M | 153.4M | 160.3M | 1.0 | 0.95 | |
Long Term Debt | 306.0M | 313.0M | 674.5M | 655.8M | 513.8M | 539.5M | |
Cash And Short Term Investments | 292.0M | 521.7M | 656.4M | 288.7M | 278.6M | 237.8M | |
Net Receivables | 47.5M | 53.0M | 96.3M | 98.4M | 105.6M | 110.8M | |
Common Stock Shares Outstanding | 41.5M | 43.7M | 45.6M | 46.5M | 52.0M | 35.9M | |
Short Term Investments | 213.7M | 421.7M | 70.8M | 184.5M | 125.3M | 137.9M | |
Liabilities And Stockholders Equity | 831.1M | 1.3B | 2.1B | 1.7B | 1.6B | 1.7B | |
Non Current Liabilities Total | 368.4M | 401.5M | 823.8M | 758.4M | 606.9M | 637.2M | |
Inventory | 58.3M | 64.7M | 98.6M | 96.1M | 104.4M | 109.6M | |
Other Current Assets | 10.8M | 12.3M | 14.8M | 15.2M | 21.5M | 22.6M | |
Other Stockholder Equity | 754.0M | 873.2M | 942.1M | 924.1M | 976.6M | 599.8M | |
Total Liab | 476.1M | 654.8M | 1.3B | 906.2M | 704.3M | 396.5M | |
Property Plant And Equipment Gross | 142.8M | 211.2M | 264.8M | 254.4M | 370.3M | 388.8M | |
Total Current Assets | 408.6M | 651.6M | 866.0M | 498.3M | 510.0M | 331.8M | |
Accumulated Other Comprehensive Income | 322K | 318K | 167K | (380K) | 247K | 259.4K | |
Short Term Debt | 4.9M | 157.1M | 382.6M | 42.8M | 17.4M | 16.6M | |
Common Stock | 42K | 44K | 45K | 46K | 52.9K | 35.1K | |
Property Plant Equipment | 104.7M | 136.7M | 264.8M | 254.4M | 292.5M | 307.2M | |
Short Long Term Debt Total | 351.9M | 541.1M | 1.1B | 763.4M | 586.0M | 348.5M | |
Net Tangible Assets | 151.0M | 423.6M | (38.7M) | 71.2M | 81.9M | 77.8M | |
Retained Earnings Total Equity | (388.2M) | (399.4M) | (253.9M) | (211.9M) | (190.7M) | (200.2M) | |
Long Term Debt Total | 276.2M | 290.6M | 306.0M | 313.0M | 360.0M | 240.7M | |
Capital Surpluse | 709.7M | 754.0M | 873.2M | 942.1M | 1.1B | 685.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 1.51 | Revenue Per Share 14.706 | Quarterly Revenue Growth 0.042 | Return On Assets 0.0376 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.